Literature DB >> 31807561

Effect of type 2 diabetes medications on fracture risk.

Cristian Guja1,2, Loreta Guja2, Rucsandra Dănciulescu Miulescu1,2.   

Abstract

Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structure/quality with increased fragility but the different diabetes medications influence the risk of fracture. While metformin and incretin-based therapies are safe, thiazolidinediones and canagliflozin (sodium-glucose cotransporter-2 inhibitor) negatively impact bone metabolism and should be avoided in subjects at increased risk of fractures. Insulin and sulphonylureas are generally safe but can increase the risk of hypoglycemia and falls with subsequent traumatic fractures. Their combination should be avoided, especially in elderly subjects. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Type 2 diabetes; bone; diabetes drugs; fracture

Year:  2019        PMID: 31807561      PMCID: PMC6861738          DOI: 10.21037/atm.2019.09.51

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  75 in total

1.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2017-04-13       Impact factor: 91.245

2.  Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Authors:  Ofri Mosenzon; Cheryl Wei; Jaime Davidson; Benjamin M Scirica; Ilan Yanuv; Aliza Rozenberg; Boaz Hirshberg; Avivit Cahn; Christina Stahre; Krzysztof Strojek; Deepak L Bhatt; Itamar Raz
Journal:  Diabetes Care       Date:  2015-09-10       Impact factor: 19.112

3.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Authors:  Yoon K Loke; Sonal Singh; Curt D Furberg
Journal:  CMAJ       Date:  2008-12-10       Impact factor: 8.262

4.  Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.

Authors:  Johanna H M Driessen; Joop P W van den Bergh; Hein A W van Onzenoort; Ronald M A Henry; Hubert G M Leufkens; Frank de Vries
Journal:  Diabetes Obes Metab       Date:  2017-01-19       Impact factor: 6.577

5.  Fracture risk in type 2 diabetes: update of a population-based study.

Authors:  L Joseph Melton; Cynthia L Leibson; Sara J Achenbach; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

6.  Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Authors:  Robert G Josse; Sumit R Majumdar; Yinggan Zheng; Amanda Adler; M Angelyn Bethel; John B Buse; Jennifer B Green; Keith D Kaufman; Helena W Rodbard; Tsvetalina Tankova; Cynthia M Westerhout; Eric D Peterson; Rury R Holman; Paul W Armstrong
Journal:  Diabetes Obes Metab       Date:  2016-10-06       Impact factor: 6.577

7.  Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

Authors:  K Melissa Hallow; Peter J Greasley; Gabriel Helmlinger; Lulu Chu; Hiddo J Heerspink; David W Boulton
Journal:  Am J Physiol Renal Physiol       Date:  2018-07-18

Review 8.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

9.  Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/eNOS pathway in a high glucose microenvironment.

Authors:  Pan Ma; Bin Gu; Wei Xiong; Baosheng Tan; Wei Geng; Jun Li; Hongchen Liu
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

10.  Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care.

Authors:  S Pscherer; K Kostev; F W Dippel; W Rathmann
Journal:  Diabetes Metab Syndr Obes       Date:  2016-02-19       Impact factor: 3.168

View more
  5 in total

1.  How Do Drugs Affect the Skeleton? Implications for Forensic Anthropology.

Authors:  Nicholas Márquez-Grant; Elisa Baldini; Victoria Jeynes; Lucie Biehler-Gomez; Layla Aoukhiyad; Nicholas V Passalacqua; Gaia Giordano; Domenico Di Candia; Cristina Cattaneo
Journal:  Biology (Basel)       Date:  2022-03-29

2.  Semaphorin3B Promotes Proliferation and Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in a High-Glucose Microenvironment.

Authors:  Quan Xing; Jingyi Feng; Xiaolei Zhang
Journal:  Stem Cells Int       Date:  2021-02-26       Impact factor: 5.443

3.  Effect of verapamil on bone mass, microstructure and mechanical properties in type 2 diabetes mellitus rats.

Authors:  Xiaodan Wu; He Gong; Xiaorong Hu; Peipei Shi; Haipeng Cen; Chenchen Li
Journal:  BMC Musculoskelet Disord       Date:  2022-04-18       Impact factor: 2.562

Review 4.  Update on the management of diabetes in long-term care facilities.

Authors:  Thaer Idrees; Iris A Castro-Revoredo; Alexandra L Migdal; Emmelin Marie Moreno; Guillermo E Umpierrez
Journal:  BMJ Open Diabetes Res Care       Date:  2022-07

5.  Bone quality analysis of jaw bones in individuals with type 2 diabetes mellitus-post mortem anatomical and microstructural evaluation.

Authors:  Teodora Rodic; Eva Maria Wölfel; Petar Milovanovic; Imke A K Fiedler; Danica Cvetkovic; Katharina Jähn; Michael Amling; Jelena Sopta; Slobodan Nikolic; Vladimir Zivkovic; Björn Busse; Marija Djuric
Journal:  Clin Oral Investig       Date:  2021-03-11       Impact factor: 3.573

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.